S&P Futures
3,632.50-4.00(-0.11%)Dow Futures
29,813.00-61.00(-0.20%)Nasdaq Futures
12,289.00+31.50(+0.26%)
Viking Therapeutics, Inc. (VKTX)
Chart Events
Performance Outlook
| Previous Close | 6.36 |
| Open | 6.42 |
| Bid | 6.56 x 2200 |
| Ask | 6.70 x 1800 |
| Day's Range | 6.42 - 6.72 |
| 52 Week Range | 3.26 - 8.87 |
| Volume | 1,073,738 |
| Avg. Volume | 1,203,896 |
| Market Cap | 487.319M |
| Beta (5Y Monthly) | 2.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.50 |
| Earnings Date | Oct 28, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.79 |
- Motley Fool
3 Stocks with Jaw-Dropping Growth Potential
Aprea Therapeutics, Viking Therapeutics, and Vaxart could all generate life-changing returns for early shareholders.
- PR Newswire
Viking Therapeutics to Present at Stifel Healthcare Conference 2020
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the Stifel Healthcare Conference 2020. The conference, which will take place November 16-18, 2020, is being conducted with a virtual format.
- Zacks Small Cap Research
VKTX: Phase 1 Trial of VK0214 Underway…
By David Bautz, PhD NASDAQ:VKTX READ THE FULL VKTX RESEARCH REPORT Business Update VK0214 Phase 1 Trial Initiated In September 2020, Viking Therapeutics, Inc. (NASDAQ:VKTX) announced the initiation of a Phase 1 clinical trial of VK0214, the company’s second thyroid beta (TRβ) receptor agonist. It is a randomized, double blind, placebo controlled, single ascending dose (SAD) and multiple ascending
